-
Product Name
Toripalimab (Synonyms: ANTI-PD-I MAB-SHANGHAI JUNSHI; Triprizumab)
- Documents
-
Description
Anti-PDCD1 / PD-1 / CD279 Antibody (Toripalimab)
-
Tested applications
ELISA
-
Species reactivity
Human PDCD1 / PD-1 / CD279
-
Alternative names
ANTI-PD-I MAB-SHANGHAI JUNSHI antibody; Triprizumab antibody; Teriprizumab antibody; Tripleitriumab antibody; Treprizumab antibody
-
Isotype
IgG4
-
Preparation
Recombinant expression and purified from CHO cells.
-
Clonality
Monoclonal
-
Formulation
0.1 M Pro-Ac, 20 mM Arg, pH 5.0
-
Storage instructions
-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.
-
Validations
SDS-PAGE
Anti-PDCD1 / PD-1 / CD279 Antibody (toripalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of Anti-PDCD1 / PD-1 / CD279 Antibody (toripalimab) is more than 95%, determined by SEC-HPLC.
Bioactivity: ELISA
Immobilized human PD-1, His Tag at 2 ug/mL can bind Anti-PDCD1 / PD-1 / CD279 Antibody (toripalimab), EC50=0.0136 ug/mL.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"